[Clinical Value of Translocator Protein Gene in Evaluating the Efficacy of FLT3-ITD/ DNMT3A R882 Double-Mutated Acute Myeloid Leukemia]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Feb;31(1):45-49. doi: 10.19746/j.cnki.issn.1009-2137.2023.01.007.
[Article in Chinese]

Abstract
in English, Chinese

Objective: To observe the clinical significance of translocator proteins (TSPO) gene in the treatment of FLT3-ITD/DNMT3A R882 double-mutated acute myeloid leukemia (AML).

Methods: Seventy-six patients with AML hospitalized in the Department of Hematology of the Affiliated People's Hospital of Ningbo University from June 2018 to June 2020 were selected, including 34 patients with FLT3-ITD mutation, 27 patients with DNMT3A R882 mutation, 15 patients with FLT3-ITD/DNMT3A R882 double mutation, as well as 19 patients with immune thrombocytopenia (ITP) hospitalized during the same period as control group. RNA was routinely extracted from 3 ml bone marrow retained during bone puncture, and TSPO gene expression was detected by transcriptome sequencing (using 2-deltadeltaCt calculation).

Results: The expression of TSPO gene in FLT3-ITD group and DNMT3A R882 group at first diagnosis was 2.02±1.04 and 1.85±0.76, respectively, which were both higher than 1.00±0.06 in control group, but the differences were not statistically significant (P=0.671, P=0.821). The expression of TSPO gene in the FLT3-ITD/DNMT3A R882 group was 3.98±1.07, wich was significantly higher than that in the FLT3-ITD group and DNMT3A R882 group, the differences were statistically significant (P=0.032, P=0.021). The expression of TSPO gene in patients who achieved complete response after chemotherapy in the FLT3-ITD/DNMT3A R882 group was 1.19±0.87, which was significantly lower than that at first diagnosis, and the difference was statistically significant (P=0.011).

Conclusion: TSPO gene may be used as an indicator of efficacy in FLT3-ITD /DNMT3A R882 double-mutated AML.

题目: 转位蛋白基因在FLT3-ITD/DNMT3A R882双突变 急性髓系白血病疗效评估中的价值.

目的: 观察转位蛋白（TSPO）基因在FLT3-ITD/DNMT3A R882双突变急性髓系白血病（AML）疗效评估中的价值.

方法: 纳入2018年6月至2020年6月在宁波大学附属人民医院血液科住院治疗的初发AML患者76例，其中伴有FLT3-ITD突变34例，伴有DNMT3A R882突变27例，伴有FLT3-ITD/DNMT3A R882双突变15例，对照组为同期住院治疗的免疫性血小板减少症（ITP）患者19例。骨髓穿刺留取骨髓3 ml，常规提取RNA，通过转录组测序方法检测TSPO基因的表达量（使用2-ΔΔCT法计算）.

结果: FLT3-ITD单突变组和DNMT3A R882单突变组初诊时TSPO基因表达量分别为2.02±1.04、1.85±0.76，均高于对照组的1.00±0.06，但比较差异无统计学意义（P=0.671，P=0.821）；双突变组初诊时TSPO基因表达量为3.98±1.07，明显高于FLT3-ITD单突变组和DNMT3A R882单突变组（P=0.032，P=0.021）；双突变组化疗后达到完全缓解的患者，达到完全缓解时的TSPO基因表达量为1.19±0.87，明显低于其初诊时的水平（P=0.011）.

结论: TSPO基因或许可以作为评估FLT3-ITD/DNMT3A R882双突变AML治疗疗效的一个指标.

Keywords: DNMT3A R882; FLT3-ITD; acute myeloid leukemia; translocator protein gene.

Publication types

  • English Abstract

MeSH terms

  • DNA (Cytosine-5-)-Methyltransferases* / genetics
  • DNA Methyltransferase 3A
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Mutation
  • Nucleophosmin
  • Prognosis
  • Receptors, GABA / genetics
  • Receptors, GABA / therapeutic use
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • DNA (Cytosine-5-)-Methyltransferases
  • DNA Methyltransferase 3A
  • Nucleophosmin
  • fms-Like Tyrosine Kinase 3
  • FLT3 protein, human
  • TSPO protein, human
  • Receptors, GABA